Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 4
Submit an article Journal homepage
94
Views
4
CrossRef citations to date
0
Altmetric
Theme: Gastrointestinal & Hepatopancreatobiliary Cancer - Review

Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy

Mustafa Khasraw Andrew Love Cancer Centre, Geelong Hospital, Geelong, VIC, Australia; School of Medicine of Deakin University, Geelong, VIC, Australia. [email protected]; Royal Melbourne Hospital, Parkville, VIC, Australia
,
Saw Yee Yap Andrew Love Cancer Centre, Geelong Hospital, Geelong, VIC, Australia; Andrew Love Cancer Centre, Geelong Hospital, Geelong, VIC, Australia
&
Sumitra Ananda Royal Melbourne Hospital, Parkville, VIC, Australia; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Western Hospital, Footscray, VIC, Australia
Pages 451-459 | Published online: 10 Jan 2014

References

  • Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9(1), 61–72 (2008).
  • Oberg K. Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao. Paulo) 67(Suppl. 1), 109–112 (2012).
  • Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am. J. Surg. Pathol. 33(4), 626–632 (2009).
  • Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 13(9), 962–972 (2000).
  • Travis WD, Rush W, Flieder DB et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am. J. Surg. Pathol. 22(8), 934–944 (1998).
  • Rindi G, Arnold R, Bosman F. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System. International Agency for Research on Cancer (IRAC), Lyon, France, 13–14 (2010).
  • Korse CM, Taal BG, Vincent A et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments. Eur. J. Cancer 48(5), 662–671 (2012).
  • Delpassand ES, Samarghandi A, Mourtada JS et al. Long-term survival, toxicity profile, and role of F-18 FDG PET/CT scan in patients with progressive neuroendocrine tumors following peptide receptor radionuclide therapy with high activity In-111 pentetreotide. Theranostics 2(5), 472–480 (2012).
  • Gulenchyn KY, Yao X, Asa SL, Singh S, Law C. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin. Oncol. (R. Coll. Radiol.) 24(4), 294–308 (2012).
  • Panzuto F, Di Fonzo M, Iannicelli E et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann. Oncol. 17(3), 461–466 (2006).
  • Rinke A, Michl P, Gress T. Medical treatment of gastroenteropancreatic neuroendocrine tumors. Cancers 4(1), 113–129 (2012).
  • Khasraw M, Townsend A, Price T, Hart J, Bell D, Pavlakis N. Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours. Intern. Med. J. 40(6), 453–458 (2010).
  • Rinke A, Müller HH, Schade-Brittinger C et al.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27(28), 4656–4663 (2009).
  • Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501–513 (2011).
  • Yao JC, Shah MH, Ito T et al.; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514–523 (2011).
  • Murray-Lyon IM, Eddleston AL, Williams R et al. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 2(7574), 895–898 (1968).
  • Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials 2(4), 327–334 (1979).
  • Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 303(21), 1189–1194 (1980).
  • Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 326(8), 519–523 (1992).
  • Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. 2(11), 1255–1259 (1984).
  • Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J. Clin. Oncol. 23(22), 4897–4904 (2005).
  • Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer 102(7), 1106–1112 (2010).
  • Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68(2), 227–232 (1991).
  • Fjällskog ML, Granberg DP, Welin SL et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92(5), 1101–1107 (2001).
  • Bajetta E, Catena L, Procopio G et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 59(5), 637–642 (2007).
  • Kunz P, Kuo T, Zahn J et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J. Clin. Oncol. 28, Abstract 4104 (2010).
  • Venook AP, Ko AH, Tempero MA et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. ASCO Meeting Abstracts 26(15 Suppl.), 15545 (2008).
  • Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18(1), 158–166 (2000).
  • Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr. Oncol. Rep. 12(1), 26–33 (2010).
  • Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2), 268–275 (2011).
  • Stupp R, Hegi ME, Mason WP et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009).
  • Kulke MH, Hornick JL, Frauenhoffer C et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 15(1), 338–345 (2009).
  • Chan JA, Stuart K, Earle CC et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 30(24), 2963–2968 (2012).
  • Kulke MH, Wu B, Ryan DP et al. A Phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig. Dis. Sci. 51(6), 1033–1038 (2006).
  • Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J. Clin. Oncol. 24(22), 3548–3554 (2006).
  • Cassier PA, Walter T, Eymard B et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 115(15), 3392–3399 (2009).
  • Ferrarotto R, Testa L, Riechelmann RP et al. Combination of capecitabine and oxaliplatin (CAPOX) is an effective option for the treatment of neuroendocrine tumours (NET). Eur. J. Cancer 47, S471 (2011).
  • Squadroni M, Pelosi G, Lorizzo K et al. Poorly differentiated neuroendocrine tumors (PD-NET): does KI67 index correlate with response to chemotherapy? Ann. Oncol. 21, 268–269 (2010).
  • Squadroni M, Stuart K, Enzinger PC et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 24(3), 401–406 (2006).
  • Ekeblad S, Sundin A, Janson ET et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors Clin. Cancer Res. 13(10), 2986–2991 (2007).
  • Kulke M, Blaszkowsky LS, Zhu AX et al. Phase I/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). ASCO Gastrointestinal Cancers Symposium Abstract 223 (2010).
  • Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117(20), 4617–4622 (2011).
  • Koumarianou A, Antoniou S, Kanakis G et al. PCombination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr. Relat. Cancer 19(1), L1–L4 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.